L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Ishikawa, Hisashi ^a   Takaki, Akinobu ^a   Tsuzaki, Ryuichiro ^a   Yasunaka, Tetsuya ^a   Koike, Kazuko ^a   Shimomura, Yasuyuki ^a   Seki, Hiroyuki ^a   Matsushita, Hiroshi ^a   Miyake, Yasuhiro ^a   Ikeda, Fusao ^a   Shiraha, Hidenori ^a   Nouso, Kazuhiro ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALPHA TOCOPHEROL; CARNITINE; CYTOKINE; FERRITIN; LONG CHAIN FATTY ACID; MESSENGER RNA; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; FAT INTAKE; VITAMIN B COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CANCER INHIBITION; CELL FUNCTION; CONTROLLED STUDY; DIET SUPPLEMENTATION; FATTY ACID TRANSPORT; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE FLORA; LIVER PROTECTION; LIVER TUMOR; MALE; METABOLOMICS; MICROBIOME; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOLECULAR DYNAMICS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR VOLUME; UPREGULATION; ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FAT INTAKE; LIVER MITOCHONDRION; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION REDUCTION REACTION; PATHOLOGY; PHARMACOLOGY;

ANIMALS; CARNITINE; DIETARY FATS; DISEASE MODELS, ANIMAL; MALE; MICE; MITOCHONDRIA, LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION-REDUCTION; UP-REGULATION; VITAMIN B COMPLEX;

EID: 84903697534     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100627     Document Type: Article

References (41)

1. Masuoka HC, Chalasani N (2013) Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci 1281: 106-122.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434-438. (Pubitemid 10057164)
3. Grattagliano I, de Bari O, Bernardo TC, Oliveira PJ, Wang DQ, et al. (2012) Role of mitochondria in nonalcoholic fatty liver disease-from origin to propagation. Clin Biochem 45: 610-618.
4. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, et al. (1999) Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282: 1659-1664. (Pubitemid 29513973)
5. Serviddio G, Bellanti F, Tamborra R, Rollo T, Romano AD, et al. (2008) Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model. Eur J Clin Invest 38: 245-252. (Pubitemid 351389142)
6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142: 1592-1609.
7. Steinhubl SR (2008) Why have antioxidants failed in clinical trials? Am J Cardiol 101: 14D-19D.
8. Mingrone G (2004) Carnitine in type 2 diabetes. Ann N Y Acad Sci 1033: 99-107.
9. Cave MC, Hurt RT, Frazier TH, Matheson PJ, Garrison RN, et al. (2008) Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract 23: 16-34. (Pubitemid 351438965)
10. Kerner J, Bieber L (1990) Isolation of a malonyl-CoA-sensitive CPT/beta-oxidation enzyme complex from heart mitochondria. Biochemistry 29: 4326-4334. (Pubitemid 20153632)
11. Chang B, Nishikawa M, Nishiguchi S, Inoue M (2005) L-carnitine inhibits hepatocarcinogenesis via protection of mitochondria. Int J Cancer 113: 719-729. (Pubitemid 40101252)
12. Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, et al. (2013) A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol 46: 141-152.
13. Kuwajima M, Fujihara H, Sei H, Umehara A, Sei M, et al. (2007) Reduced carnitine level causes death from hypoglycemia: possible involvement of suppression of hypothalamic orexin expression during weaning period. Endocr J 54: 911-925. (Pubitemid 351346774)
14. Gohil K, Vasu VT, Cross CE (2010) Dietary alpha-tocopherol and neuromuscular health: search for optimal dose and molecular mechanisms continues! Mol Nutr Food Res 54: 693-709.
15. Pilger A, Rudiger HW (2006) 8-Hydroxy-2′-deoxyguanosine as a marker of oxidative DNA damage related to occupational and environmental exposures. Int Arch Occup Environ Health 80: 1-15. (Pubitemid 44489988)
16. Nagashima K, Hisada T, Sato M, Mochizuki J (2003) Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol 69: 1251-1262. (Pubitemid 36204859)
17. Takaki A, Kawai D, Yamamoto K (2013) Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci 14: 20704-20728.
18. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B (2011) Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 54: 773-794.
19. Begriche K, Igoudjil A, Pessayre D, Fromenty B (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6: 1-28.
20. Mittler R, Vanderauwera S, Suzuki N, Miller G, Tognetti VB, et al. (2011) ROS signaling: the new wave? Trends Plant Sci 16: 300-309.
21. Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, et al. (2011) Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 53: 448-457.
22. Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, et al. (2010) L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis-a randomized and controlled clinical trial. Am J Gastroenterol 105: 1338-1345.
23. Xia Y, Li Q, Zhong W, Dong J, Wang Z, et al. (2011) L-carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function. Diabetol Metab Syndr 3: 31.
24. Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, et al. (2011) Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr 93: 799-808.
25. Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH (2006) Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol 40 Suppl 1: S51-60. (Pubitemid 44309544)
26. Sokol RJ, McKim JM, Jr., Goff MC, Ruyle SZ, Devereaux MW, et al. (1998) Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology 114: 164-174. (Pubitemid 28020966)
27. Selman C, McLaren JS, Collins AR, Duthie GG, Speakman JR (2013) Deleterious consequences of antioxidant supplementation on lifespan in a wild-derived mammal. Biol Lett 9: 20130432.
28. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1675-1685.
29. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, et al. (2011) Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305: 1659-1668.
30. Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T (2010) Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 341: c5702.
31. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297: 842-857. (Pubitemid 46333949)
32. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J (2008) Body iron metabolism and pathophysiology of iron overload. Int J Hematol 88: 7-15.
33. Watt RK (2011) The many faces of the octahedral ferritin protein. Biometals 24: 489-500.
34. Bergmann OM, Mathahs MM, Broadhurst KA, Weydert JA, Wilkinson N, et al. (2008) Altered expression of iron regulatory genes in cirrhotic human livers: clues to the cause of hemosiderosis? Lab Invest 88: 1349-1357.
35. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al. (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482: 179-185.
36. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, et al. (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499: 97-101.
37. Jo M, Nishikawa T, Nakajima T, Okada Y, Yamaguchi K, et al. (2011) Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. J Gastroenterol 46: 809-821.
38. Nishikawa T, Nakajima T, Katagishi T, Okada Y, Jo M, et al. (2009) Oxidative stress may enhance the malignant potential of human hepatocellular carcinoma by telomerase activation. Liver Int 29: 846-856.
39. Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, et al. (2013) Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J Gastroenterol 48: 1249-1258.
40. Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, et al. (2012) Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 3: 883.
41. Huang H, Liu N, Guo H, Liao S, Li X, et al. (2012) L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro. PLoS One 7: e49062.